Exact Sciences Corporation (NASDAQ:EXAS) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 16,290,094 shares, a decrease of 11.3% from the August 31st total of 18,365,552 shares. Currently, 14.0% of the company’s stock are sold short. Based on an average daily trading volume, of 1,406,353 shares, the short-interest ratio is presently 11.6 days.

A number of equities analysts have weighed in on the company. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 price target (up previously from $45.00) on shares of Exact Sciences Corporation in a research report on Thursday, September 21st. Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 price objective on the stock. in a report on Thursday, July 6th. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price objective (up from $45.00) on shares of Exact Sciences Corporation in a report on Tuesday. BidaskClub raised shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Finally, BTIG Research reissued a “buy” rating and issued a $45.00 price objective (up previously from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $43.11.

In related news, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thomas D. Carey bought 2,500 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average cost of $37.71 per share, for a total transaction of $94,275.00. Following the transaction, the director now owns 60,858 shares in the company, valued at approximately $2,294,955.18. The disclosure for this purchase can be found here. Insiders have sold 237,444 shares of company stock valued at $10,412,421 over the last ninety days. 4.00% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Fortaleza Asset Management Inc. bought a new position in shares of Exact Sciences Corporation during the second quarter valued at about $106,000. Krilogy Financial LLC boosted its holdings in Exact Sciences Corporation by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares during the last quarter. Financial Architects Inc boosted its holdings in Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares during the last quarter. Finally, Johnson Financial Group Inc. boosted its holdings in Exact Sciences Corporation by 25.9% during the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 85.23% of the company’s stock.

Exact Sciences Corporation (NASDAQ:EXAS) opened at 49.12 on Wednesday. The stock’s 50 day moving average is $42.56 and its 200 day moving average is $34.76. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $50.65. The firm’s market capitalization is $5.85 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The business had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. Analysts predict that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

WARNING: “Exact Sciences Corporation (EXAS) Short Interest Update” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/04/exact-sciences-corporation-exas-short-interest-update.html.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.